drugset / Trial / NCT01593488
Liposomal Cytarabine in the Treatment of Central Nervous System Resistant or Relapsed Acute Lymphoblastic Leukemia in Children
Phase 2
Unknown
31 enrolled
National Cancer Institute, Naples
IRCCS Azienda Ospedaliero-Universitaria di Bologna · collabSantobono-Pausilpon Hospital · collabUniversity of Bologna · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to describe the activity and toxicity of a new formulation of cytarabine called liposomal cytarabine given into the central nervous system for the treatment of central nervous system localization of acute lymphoblastic leukemia (ALL) in children and adolescents.
Timeline
- Start
- 2012-03
- Primary completion
- 2024-12
- Completion
- 2024-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cytarabine | Small molecule | — | Intrathecal |